Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Internal Medicine, Family Medicine
Credits Available: 3.25 AMA PRA Category 1 Credit™

Since the beginning of the COVID-19 pandemic, there have been reservations regarding the risks of using immunosuppressive or immunomodulating agents to treat patients with multiple sclerosis (MS) in case these treatments increase infectious disease risk or reduce vaccine efficacy. Many MS patients take disease-modifying therapies (DMTs) to prevent new symptoms such as muscle weakness, poor coordination, and/or impaired vision while mitigating disease progression.

For many years, the treatment paradigm has been to “treat early and never stop”, but given issues that arose during the COVID-19 pandemic, this idea became much more challenging. While it appears we are in a nadir with respect to COVID infections, the risk of COVID remains and is of particular concern for our patients with MS.

MS treatment in the context of COVID-19 risk or infection has been exceptionally challenging. Accordingly, healthcare providers have had reservations and concerns regarding deciding what are the safest and most effective treatment strategies taking into consideration all of the risks and potential complications when addressing both MS and COVID-19.

Clinicians caring for patients with MS require educational programs to stay informed of the recommended best use of DMTs and to be aware of the latest guidelines for safely treating MS in the context of COVID-19.

This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with MS in the context of COVID-19.


CME/CE Accreditation Information

Itinerary

Meet and Greet

Please join me for a brief kick off where you'll have a chance to greet other group members and discuss our collective goals and priorities for the next few weeks. I’m really looking forward to seeing you.

Addressing the Impact of COVID-19 on MS Care - Baseline Assessment

The following questions are designed to assess your knowledge and practice related to the impact that COVID-19 has had in the care of patients with MS.

Module 1 - Initiating, Continuing, and/or Switching DMTs in the Context of COVID

This module gives consideration to the risks vs. benefits of each MS disease modifying therapy in the context of COVID-19.

Module 2 - COVID-19 Infection in People with MS

This module covers each specific DMT category with respect to balancing concerns of COVID-19 infection while attempting to control a patient’s MS.

Addressing the Impact of COVID-19 on MS Care - Final Assessment

The following questions are designed to assess your gained knowledge and practice related to the impact that COVID-19 has had in the care of patients with MS.

Live Group Discussion #1

This virtual live discussion provides an opportunity for the group to convene with their group leader to discuss aspects of the self-study learning modules.

MS COVID Group Task: Bill's Case

This group task activity has been designed for the learner to explore a patient case study and to apply the knowledge they have learned throughout the activity to determine the most appropriate way to treat the patient.

MS COVID Group Task: Mary's Case

This group task activity has been designed for the learner to explore a patient case study and to apply the knowledge they have learned throughout the activity to determine the most appropriate way to treat the patient.

MS Care in Action

In light of the information reviewed and discussed during this program, please share an action plan ;that you will implement to improve the outcomes for your patients with MS.

Live Group Discussion #2

This virtual live discussion provides an opportunity for the group to convene with their group leader to discuss aspects of the self-study learning modules.

Curriculum is Currently Closed

Thank you for your interest. Currently, the curriculum is closed for enrollment but we encourage you to keep an eye out for future opportunities or alternative programs that might align with your educational goals.

View Other Offerings

Completed Groups

Robert Bermel
Director
Completed
Shiv Saidha, MBBCh
Professor of Neurology
Completed
Jessica Szpak, PA-C
PA-C, MSCS
Completed
Denise Bruen, ANP-BC, MSCN
Nurse Practitioner
Completed
Derrick Robertson, MD
Associate Professor of Neurology
Completed
Giovanna Manzano, MD
Neuroimmunologist & MS Specialist/ Instructor in Neurology
Completed
MA
Mirla Avila, MD
Associate Professor of Neurology
Completed
Collin Jakubecz, PharmD
Clinical Pharmacy Specialist- Neurology/MS
Completed
Yasir Jassam, MBChB MRCP(UK) FRCP FAAN
Director of Multiple Aclerosis and Neuroimmunology program, Chair of the Dept. of Neurology and Psychiatry
Completed
Giovanna Manzano, MD
Neuroimmunologist & MS Specialist/ Instructor in Neurology
Completed